ORAGENICS INC (OGEN)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$0.51+2.31%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · OGEN
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | — | — | 0.0 | 0.1 | 0.1 | — | — | — | 0.0 | 0.0 | 0.0 | 0.9 | 1.0 | 1.3 | 1.4 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.9 | 1.0 | 1.3 | 1.4 |
| Gross Profit | — | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.6 | 0.7 | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | — | — | — | — | — | — | — | — | — | — | — | 3.5 | 3.3 | 7.5 | 5.0 | 5.6 |
| R&D Expenses | 3.4 | 2.4 | 4.1 | 15.5 | 10.1 | 10.6 | 22.1 | 12.1 | 6.0 | 3.5 | 4.8 | 8.7 | 3.1 | 9.4 | 7.9 | 2.4 |
| Operating Income | (10.5) | (9.4) | (10.6) | (20.9) | (14.4) | (15.8) | (26.6) | (15.9) | (10.0) | (6.7) | (8.5) | (11.8) | (5.8) | (16.2) | (12.4) | (7.3) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 0.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | 0.0 | 0.2 | 0.0 | 0.1 | 0.0 | 0.0 | 0.7 | 0.3 |
| Interest & Investment Income | 0.2 | 0.2 | 0.0 | 0.2 | 0.1 | 0.1 | 0.1 | 0.3 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Interest Expenses | — | — | — | (0.2) | (0.1) | (0.1) | (0.1) | — | (0.1) | 0.2 | (0.0) | 0.1 | (0.0) | (0.0) | 0.6 | 0.3 |
| Other Non-Operating Income / Expenses | 0.2 | (0.6) | (0.0) | 0.2 | 0.1 | 0.1 | 0.2 | 0.3 | 0.1 | (0.0) | 0.0 | (0.1) | 0.0 | 0.1 | (0.7) | — |
| EBT, Incl. Unusual Items | — | (10.0) | (10.6) | (20.7) | (14.3) | (15.7) | (26.4) | (15.6) | (9.9) | (6.7) | (8.5) | (11.8) | (5.8) | (16.1) | (13.1) | (7.7) |
| Income Tax Expense | — | (0.1) | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | (0.7) |
| Net Income | ||||||||||||||||
| Net Income | (984.5) | (9.8) | (10.6) | (20.7) | (14.3) | (15.7) | (26.4) | (15.6) | (9.9) | (6.7) | (7.0) | (11.7) | (5.8) | (16.1) | (13.1) | (7.7) |
| Per Share | ||||||||||||||||
| Basic EPS | (222.30) | (4.56) | (1.60) | (9.18) | (7.11) | (8.09) | (0.47) | — | — | — | — | — | — | — | — | — |
| Diluted EPS | (222.30) | (4.56) | (1.60) | (9.18) | (7.11) | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 4.4 | 2.2 | 6.6 | 2.2 | 2.0 | 1.9 | 56.5 | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 4.4 | 2.2 | 6.6 | 2.2 | 2.0 | — | — | — | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | — | — | (20.9) | (14.4) | (15.7) | (26.6) | (15.8) | (10.0) | (6.7) | (8.5) | (11.7) | (5.8) | (16.1) | (12.4) | (7.3) |
| EBIT | (10.5) | (9.4) | (10.6) | (20.9) | (14.4) | (15.8) | (26.6) | (15.9) | (10.0) | (6.7) | (8.5) | (11.8) | (5.8) | (16.2) | (12.4) | (7.3) |
| Effective Tax Rate | — | — | — | — | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | 9.6% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.